Your session is about to expire
← Back to Search
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Phase 2
Recruiting
Research Sponsored by Hoag Memorial Hospital Presbyterian
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial suggests that PyL, a novel PET tracer, may be more effective than the standard of care imaging for detecting prostate cancer metastases.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Detection of unsuspected metastases in biochemically recurrent prostate cancer
Detection of unsuspected metastases in high risk prostate cancer
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: High risk prostate cancerExperimental Treatment1 Intervention
DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
Group II: Biochemically recurrent prostate cancerExperimental Treatment1 Intervention
DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
Find a Location
Who is running the clinical trial?
Hoag Memorial Hospital PresbyterianLead Sponsor
36 Previous Clinical Trials
17,018 Total Patients Enrolled
1 Trials studying Prostate Cancer
100 Patients Enrolled for Prostate Cancer
Deborah Fridman, PsyD, RNStudy DirectorHoag Memorial Hospital Presbyterian
1 Previous Clinical Trials
60 Total Patients Enrolled